95791-03-0Relevant articles and documents
Hydrogen-Bonding Assisted Catalytic Kinetic Resolution of Acyclic β-Hydroxy Amides
Porey, Arka,Mondal, Bhaskar Deb,Guin, Joyram
supporting information, p. 8786 - 8791 (2021/03/17)
Enantioenriched acyclic α-substituted β-hydroxy amides are valuable compounds in chemical, material and medicinal sciences, but their enantioselective synthesis remains challenging. A catalytic kinetic resolution (KR) of such amides with selectivity factor(s) up to >200 is developed via enantioselective acylation of primary alcohol with N-heterocyclic carbene. An enhanced selectivity for the catalytic KR process is realized using cyclic tertiary amine as base additive. Diastereomeric transition state models for the process are proposed to rationalize the origin of enantioselectivity.
A stereodivergent approach to carbahexofuranoses: Synthesis of carba-α-d-glucofuranose, carba-β-d-altrofuranose, carba-α-d-allofuranose, carba-β-d-idofuranose, carba-α-d- galactofuranose and carba-β-d-talofuranose
Kulkarni, Mukund G.,Borhade, Ajit S.,Shaikh, Yunnus B.,Dhondge, Attrimuni P.,Birhade, Deekshaputra R.,Dhatrak, Nagorao R.
, p. 5559 - 5562 (2011/11/06)
A stereodivergent route, starting from d-glyceraldehyde derivative, employing Wittig olefination-Claisen rearrangement protocol is reported for the synthesis of six novel carbahexofuranoses - carba-α-d-glucofuranose, carba-β-d-altrofuranose, carba-α-d-all
Practical syntheses of enantiomerically pure key intermediates of opioid receptor-like 1 (ORL1) antagonists
Yoshizumi, Takashi,Ohno, Akio,Tsujita, Tomohiro,Takahashi, Hirobumi,Okamoto, Osamu,Hayakawa, Ichiro,Kigoshi, Hideo
experimental part, p. 1153 - 1162 (2009/12/04)
Practical syntheses of enantiomerically pure key intermediates of opioid receptor-like 1 (ORL1) antagonists are described. Our synthetic methodology features the preparation of multigram quantities of seven-membered key intermediate (-)-3 and six-membered one (-)-4 without the use of toxic tin reagents. In the case of (-)-3, the key step involved diastereoselective reduction using a sterically hindered reducing reagent. Our methodology allows for facile scale-up to afford the products in multigram quantities [in the case of (-)-4, >100-g quantities). These convenient approaches facilitate structure-activity relationship studies including in vivo cardiovascular adverse effects. Georg Thieme Verlag Stuttgart.
Total synthesis and evaluation of C25-benzyloxyepothilone C for tubulin assembly and cytotoxicity against MCF-7 breast cancer cells
Hutt, Oliver E.,Reddy, Bollu S.,Nair, Sajiv K.,Reiff, Emily A.,Henri, John T.,Greiner, Jack F.,Chiu, Ting-Lan,VanderVelde, David G.,Amin, Elizabeth A.,Himes, Richard H.,Georg, Gunda I.
scheme or table, p. 4904 - 4906 (2009/05/27)
The total synthesis of C25-benzyloxy epothilone C is described. A sequential Suzuki-Aldol-Yamaguchi macrolactonization strategy was utilized employing a novel derivatized C8-C12 fragment. The C25-benzyloxy analog exhibited significantly reduced biological activity in microtubule assembly and cytotoxicity assays. Molecular modeling simulations indicated that excessive steric bulk in the C25 position may reduce activity by disrupting key hydrogen bonds that are crucial for epothilone binding to β-tubulin.
CYCLOALKANOPYRIDINE DERIVATIVE
-
, (2010/11/24)
Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.
USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES
-
, (2008/06/13)
A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A) or a pharmaceutically acceptable salt thereof; and compounds for use in the method.
BIFUNCTIONAL CHIRAL SYNTHONS VIA BIOCHEMICAL METHODS. 4. CHIRAL PRECURSORS TO (+)-BIOTIN AND (-)-A-FACTOR.
Wang, Yi-Fong,Sih, Charles J.
, p. 4999 - 5002 (2007/10/02)
The chirons 3 and 4, derived from enzymic enantioselective hydrolysis of 1 and 2, are converted into the chiral lactones 5 and 6, key precursors to (+)-biotin and (-)-A-factor, respectively.
